MedTrace Logo

A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan

NCT01752075 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-11-18

No results posted yet for this study

Summary

The REVLIMID Registry will provide safety data from a large cohort of Taiwanese patients treated with REVLIMID. In addition, the registry will provide efficacy data and outcomes in a real-world setting (versus a clinical trial).

Conditions

Interventions

DRUG

Revlimid

The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Ye Hua, MD · Celgene

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2013-07-12
Completion
2013-07-19

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01752075 on ClinicalTrials.gov